Route 92 Medical announced today that it filed a patent infringement lawsuit against Balt related to its Tenzing catheter delivery technology.
The suit alleges the infringement of five U.S. patents held by Route 92 that protect the Tenzing technology. San Mateo-based Route 92 filed its complaint on Aug. 6, 2025, in the U.S. District Court for the District of Delaware.
This marks the latest patent spat for the company, which earlier this year settled litigation filed against Q’Apel Medical over Tenzing IP.
Route 92 develops a suite of reperfusion and access systems leveraging the patented Tenzing delivery catheter. The products aim to improve the efficiency of endovascular thrombectomy procedures. The company designed its technology to enable the quick restoration of blood flow to the brain following acute ischemic stroke.
Tenzing delivery catheters — first clinically used in 2019 — have the protection of a global patent portfolio that includes more than 30 U.S. patents.
“We believe Route 92 Medical has a differentiated portfolio of complete solutions for neurovascular interventional procedures each supported by our proprietary and patented Tenzing delivery technology,” said Dr. Tony Chou, founder and CEO of Route 92 Medical. “Results using our products published in peer-reviewed journals demonstrate high rates of ability to reach and remove a clot on the first pass. These publications include both our FreeClimb reperfusion systems and HiPoint reperfusion systems featuring the Monopoint approach, all featuring Tenzing delivery technology.
“We believe the market success of these products is a testament to the clinical outcomes that are achieved with their use. We will continue to vigorously defend the patents that protect our innovations worldwide.”
